Interfacial Inhibitors

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 2015 Aug 4

PMID 26235949

Citations 21

Authors

Yves Pommier

Evgeny Kiselev

Christophe Marchand

Affiliations

Soon will be listed here.

Abstract

Targeting macromolecular interface is a general mechanism by which natural products inactivate macromolecular complexes by stabilizing normally transient intermediates. Demonstrating interfacial inhibition mechanism ultimately relies on the resolution of drug-macromolecule structures. This review focuses on medicinal drugs that trap protein-DNA complexes by binding at protein-DNA interfaces. It provides proof-of-concept and detailed structural and mechanistic examples for topoisomerase inhibitors and HIV integrase inhibitors. Additional examples of recent interfacial inhibitors for protein-DNA interfaces are provided, as well as prospects for targeting previously 'undruggable' targets including transcription, replication and chromatin remodeling complexes. References and discussion are included for interfacial inhibitors of protein-protein interfaces.

Citing Articles

Structural Chemistry of Helicase Inhibition.

Selvaratnam L, Willson T, Schapira M J Med Chem. 2025; 68(4):4022-4039.

PMID: 39933052 PMC: 11873931. DOI: 10.1021/acs.jmedchem.4c01909.

Noncanonical inhibition of topoisomerase II alpha by oxidative stress metabolites.

Flor A, Wolfgeher D, Kron S Redox Biol. 2025; 80:103504.

PMID: 39879737 PMC: 11810846. DOI: 10.1016/j.redox.2025.103504.

Synthesis and Biological Activity of a New Indenoisoquinoline Copper Derivative as a Topoisomerase I Inhibitor.

Molinaro C, Wambang N, Pellegrini S, Henry N, Lensink M, Germain E Int J Mol Sci. 2023; 24(19).

PMID: 37834037 PMC: 10572568. DOI: 10.3390/ijms241914590.

Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors.

Madkour M, Ramadan W, Saleh E, El-Awady R Ann Med. 2023; 55(1):2203946.

PMID: 37092854 PMC: 10128461. DOI: 10.1080/07853890.2023.2203946.

Alkyne Activation in the Diversity Oriented Synthesis of sp -Rich Scaffolds: A Biased Library Approach for Targeting Polynucleotides (DNA/RNA).

Chen S, Priebbenow D, Somkhit J, Scullino C, Agama K, Pommier Y Chemistry. 2022; 28(71):e202201925.

PMID: 36069042 PMC: 10092545. DOI: 10.1002/chem.202201925.

References

Pommier Y . Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006; 6(10):789-802. DOI: 10.1038/nrc1977. View

Vos S, Tretter E, Schmidt B, Berger J . All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol. 2011; 12(12):827-41. PMC: 4351964. DOI: 10.1038/nrm3228. View

Koster D, Croquette V, Dekker C, Shuman S, Dekker N . Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB. Nature. 2005; 434(7033):671-4. DOI: 10.1038/nature03395. View

Chrencik J, Staker B, Burgin A, Pourquier P, Pommier Y, Stewart L . Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol. 2004; 339(4):773-84. DOI: 10.1016/j.jmb.2004.03.077. View

Laponogov I, Sohi M, Veselkov D, Pan X, Sawhney R, Thompson A . Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol. 2009; 16(6):667-9. DOI: 10.1038/nsmb.1604. View

Capranico G, Kohn K, Pommier Y . Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res. 1990; 18(22):6611-9. PMC: 332618. DOI: 10.1093/nar/18.22.6611. View

Hare S, Smith S, Metifiot M, Jaxa-Chamiec A, Pommier Y, Hughes S . Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011; 80(4):565-72. PMC: 3187526. DOI: 10.1124/mol.111.073189. View

Agrawal R, Frank J . Structural studies of the translational apparatus. Curr Opin Struct Biol. 1999; 9(2):215-21. DOI: 10.1016/S0959-440X(99)80031-1. View

Staker B, Hjerrild K, Feese M, Behnke C, Burgin Jr A, Stewart L . The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A. 2002; 99(24):15387-92. PMC: 137726. DOI: 10.1073/pnas.242259599. View

10.

Wu C, Li T, Farh L, Lin L, Lin T, Yu Y . Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science. 2011; 333(6041):459-62. DOI: 10.1126/science.1204117. View

11.

Bax B, Chan P, Eggleston D, Fosberry A, Gentry D, Gorrec F . Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature. 2010; 466(7309):935-40. DOI: 10.1038/nature09197. View

12.

Fortune J, Osheroff N . Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol. 2000; 64:221-53. DOI: 10.1016/s0079-6603(00)64006-0. View

13.

Pommier Y, Leo E, Zhang H, Marchand C . DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010; 17(5):421-33. PMC: 7316379. DOI: 10.1016/j.chembiol.2010.04.012. View

14.

Harms J, Wilson D, Schluenzen F, Connell S, Stachelhaus T, Zaborowska Z . Translational regulation via L11: molecular switches on the ribosome turned on and off by thiostrepton and micrococcin. Mol Cell. 2008; 30(1):26-38. DOI: 10.1016/j.molcel.2008.01.009. View

15.

Kesters D, Thompson A, Brams M, van Elk R, Spurny R, Geitmann M . Structural basis of ligand recognition in 5-HT3 receptors. EMBO Rep. 2012; 14(1):49-56. PMC: 3537142. DOI: 10.1038/embor.2012.189. View

16.

Pommier Y, Cherfils J . Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol Sci. 2005; 26(3):138-45. DOI: 10.1016/j.tips.2005.01.008. View

17.

Renault L, Guibert B, Cherfils J . Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor. Nature. 2003; 426(6966):525-30. DOI: 10.1038/nature02197. View

18.

Pommier Y . Drugging topoisomerases: lessons and challenges. ACS Chem Biol. 2012; 8(1):82-95. PMC: 3549721. DOI: 10.1021/cb300648v. View

19.

Wohlkonig A, Chan P, Fosberry A, Homes P, Huang J, Kranz M . Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010; 17(9):1152-3. DOI: 10.1038/nsmb.1892. View

20.

Singh S, Kaelin D, Wu J, Miesel L, Tan C, Meinke P . Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents. ACS Med Chem Lett. 2014; 5(5):609-14. PMC: 4027601. DOI: 10.1021/ml500069w. View